Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

NCT06545942 is registered in ClinicalTrials.gov with MOMA Therapeutics as lead sponsor.

NCT NCT06545942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06545942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
MOMA Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
August 13, 2024
Completion date
November 30, 2027
Enrollment
220 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, breast cancer, homologous recombination deficiency, metastatic solid tumor, ovarian cancer, pancreas cancer, prostate cancer